Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study

Vianney Tricou; Brandon Essink; John E. Ervin; Mark Turner; Ian Escudero; Martina Rauscher; Manja Brose; Inge Lefevre; Astrid Borkowski; Derek Wallace

doi:10.1371/journal.pntd.0011124

Abstract

Background

Yellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently no recommended vaccine available for dengue-naïve individuals. This phase 3 study assessed the immunogenicity and safety of concomitant and sequential administration of YF (YF-17D) and tetravalent dengue (TAK-003) vaccines in healthy adults aged 18–60 years living in areas of the US non-endemic for either virus.

Methods

Participants were randomized 1:1:1 to receive the following vaccinations at Months 0, 3, and 6, respectively: YF-17D+placebo, TAK-003, and TAK-003 (Group 1); TAK-003+placebo, TAK-003, and YF-17D (Group 2); or YF-17D+TAK-003, TAK-003, and placebo (Group 3). The primary objective was to demonstrate non-inferiority (upper bound of 95% confidence interval [UB95%CI] of difference <5%) of YF seroprotection rate one month following concomitant administration of YF-17D and TAK-003 (Group 3) compared with YF-17D plus placebo (Group 1). The secondary objectives included demonstration of non-inferiority of YF and dengue geometric mean titers (GMTs) (UB95%CI for GMT ratio <2.0), and safety.

Results

900 adults were randomized. YF seroprotection rates one month post-YF-17D (Month 1) were 99.5% and 99.1% in Group 1 and 3, respectively, and non-inferiority was demonstrated (UB95%CI = 2.69% i.e. <5%). Non-inferiority was also demonstrated for GMTs against YF one month post-YF-17D, and against DENV-2, -3, and -4 (UB95%CI <2), but not DENV-1 (UB95%CI: 2.22), one month post-second TAK-003 vaccination. Adverse event rates following TAK-003 were consistent with previous results, and no important safety risks were identified.

Conclusions

In this study, YF-17D vaccine and TAK-003 were immunogenic and well tolerated when sequentially or concomitantly administered. The non-inferiority of immune responses to YF-17D and TAK-003 was demonstrated for concomitant administration of the 2 vaccines compared to separate vaccination, except against DENV-1 but with GMTs similar to those observed in other TAK-003 trials.

Trial registration

ClinicalTrials.gov identified: NCT03342898.

Author summary

Dengue and yellow fever are diseases endemic to tropical regions, often occurring in the same areas. There are highly effective vaccines against yellow fever, but there remains an unmet need for a dengue vaccine which can be used in people regardless of previous dengue infection. As multiple vaccines are often given together, particularly in travel medicine, we investigated the immunogenicity and safety of co-administration and sequential administration of a yellow fever vaccine and a tetravalent dengue vaccine (TAK-003) in adults living in areas of the US non-endemic for either disease. Most participants did not have pre-existing antibodies to either disease. We found that there was no reduction in immune response to the yellow fever vaccine when given at the same time as the dengue vaccine. There was also no reduction in response to dengue serotypes 2, 3, and 4, but this could not be established for the response to serotype 1. When sequentially administered, temporary increases were observed in yellow fever seroprotection rates after receipt of TAK-003, and in dengue seropositivity rates after receipt of the yellow fever vaccine, but these differences among groups were no longer seen by the end of the study. Both vaccines were well tolerated with acceptable safety profiles.

Citation: Tricou V, Essink B, Ervin JE, Turner M, Escudero I, Rauscher M, et al. (2023) Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLoS Negl Trop Dis 17(3): e0011124. https://doi.org/10.1371/journal.pntd.0011124

Editor: Hannah E. Clapham, National University Singapore Saw Swee Hock School of Public Health, SINGAPORE

Received: June 24, 2022; Accepted: January 29, 2023; Published: March 8, 2023

Copyright: © 2023 Tricou et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants data supporting the results reported in this article, will be made available within three months from initial request to researchers who provide a methodologically sound proposal. Data requests will be reviewed by Vivli and Takeda for completeness and other parameters (relating to scope, system-compatibility, and meeting sponsor policies) and will then be reviewed by an independent review panel. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection and requirements for consent and anonymization. Data requests should follow the process described in the Data Sharing section on https://vivli.org/about/data-request-review-process/ and https://vivli.org/ourmember/takeda/.

Funding: This study was funded by Takeda Pharmaceuticals, and the sponsor played role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.

Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: VT, IE, MR, MB, IL and DW are full-time employees of Takeda. AB was employee of Takeda at the time of the study (current affiliation of AB: HilleVax GmbH, Zurich, Switzerland). BE, JEE, and MT received funding from Takeda Vaccines to perform the trial.

Introduction

Dengue, a disease caused by the dengue flavivirus (DENV), is endemic in 129 countries worldwide, and was named by the World Health Organization (WHO) as one of the top ten threats to human health in 2019 [1]. DENV is predominantly transmitted by Aedes aegypti mosquitoes, with four virus serotypes (DENV-1, -2, -3, and -4) broadly co-circulating in endemic regions [2]. While the distribution of A. aegypti has been increasing with global temperature changes, risk of DENV transmission remains predominantly in tropical regions of South-East Asia, Central and South America, the Caribbean, and Sub-Saharan Africa [3]. DENV causes a range of symptoms from mild flu-like disease to potentially fatal severe dengue in a small proportion of individuals. Annually, there are an estimated 58–96 million symptomatic DENV infections, with 10.5 million cases requiring hospitalization [2, 4].

Yellow fever (YF) virus, the archetypal flavivirus, is closely related to DENV and is predominantly transmitted by Aedes and Haemogogus mosquitoes [5]. YF is endemic to tropical regions of Sub-Saharan Africa and South America, leading to partial overlap with DENV distribution [6]. YF virus causes mild symptoms in the majority of patients, however, a small proportion may go on to develop severe hemorrhagic symptoms, with a high mortality rate of approximately 50% [5, 7]. Vaccines against YF have been used since the 1930s and currently the only type of YF vaccine available is based on the attenuated 17D strain, derived from a wild-type YF virus isolated in Ghana in 1927 [8]. The highly efficacious YF-17D vaccines are administered as a single subcutaneous (SC) injection and seroconversion rates of >90% are reported by most studies [9]. YF neutralizing antibodies have been shown to persist for at least 40 years following single vaccination, indicating lifelong protection for vaccine recipients [10]. In addition to providing individual protection to those potentially exposed to YF virus, YF vaccination prevents the international spread of the disease by reducing the risk of importing the virus to non-endemic areas that contain competent YF vectors. In line with International Health Regulations, many countries require proof of YF vaccination in travelers arriving from areas at risk of YF virus transmission [11].

While a highly effective vaccine against YF has been available for decades, there remains an unmet need for an effective vaccine against dengue which is suitable for use in individuals without prior exposure to the virus. TAK-003 is a tetravalent dengue vaccine candidate based on a DENV-2 backbone, which was originally designed and constructed by scientists at the Division of Vector-Borne Diseases of the US Centers for Disease Control and Prevention (CDC) [12]. The DENV-2 strain in the vaccine (TDV-2) is based on an attenuated laboratory-derived virus, DENV-2 PDK-53 [13]. Recombinant serotype 1, 3, and 4 viruses (TDV-1, -3, and -4) were created by substituting pre-membrane and envelope genes of the DENV-2 backbone with those of the corresponding serotype [12, 14, 15]. TAK-003 has been shown to be immunogenic, efficacious, and well tolerated in phase 1, 2, and 3 studies, irrespective of baseline serostatus [16–23]. Overall vaccine efficacy in preventing virologically confirmed dengue (the primary endpoint) was estimated as 80.2% (95% confidence interval [CI]: 73.3–85.3%) in the first 12 months of the ongoing phase 3 efficacy study in children and adolescents living in endemic areas of Asia and Latin America, with efficacies of 76.1% (68.5–81.9%) and 66.2% (49.1–77.5%) in baseline seropositive and seronegative participants, respectively, after the 18-month period defined for secondary efficacy endpoints [23, 24]. More recently, two-year and three-year follow-up data supported the long-term safety and efficacy of TAK-003 against dengue disease and hospitalization [25, 26].

The overlapping geographical distributions of YF and dengue mean that travelers to endemic areas could be offered both vaccines. Concomitant administration increases the likelihood that recipients will receive all the necessary vaccines [27]. However, the potential for interactions between YF-17D and TAK-003, together with the effect of serological cross-reactions from sequential flavivirus exposure needs to be assessed. Flavivirus cross-reactive antibodies have been observed in sera from patients hospitalized with severe dengue or Japanese encephalitis (JE), with ≥4-fold increases in antibody titers against dengue, JE, and/or YF viruses observed when convalescent sera were compared with acute phase [28]. Cross-reactions have also been observed in previous dengue vaccine studies. For example, immune interference has been observed in adult and pediatric trials with YF-17D and CYD-TDV, the only currently commercially available dengue vaccine, which is licensed for individuals with evidence of previous DENV infection, with concomitant administration leading to reduced geometric mean titers (GMTs) against DENV [29, 30]. In a previous phase 1 study of a monovalent DENV-2 vaccine, participants with previous YF exposure developed cross-reactive antibodies to all four DENV serotypes, compared with low seroconversion rates to DENV-1, -3, and -4 in YF-naïve participants [31]. Similarly, YF priming resulted in a broader antibody response in a separate study of monovalent DENV-1, -2, -3, and -4 vaccines [32]. However, pre-existing YF antibodies have also been shown to impair response to vaccination against tick-borne encephalitis [33], and concomitant administration of YF and measles, mumps, and rubella (MMR) vaccine led to reduced immunogenicity of both vaccines [34].

The aim of this study was to assess the immunogenicity and safety of TAK-003 and YF-17D administered either concomitantly or sequentially in healthy adults aged 18–60 years living in areas non-endemic for either disease.

Methods

Ethics statement

The study was performed in accordance with the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonized Tripartite Guideline and Good Clinical Practice (ICH E6(R2)-GCP) ethical principles that have their origin in the Declaration of Helsinki, and applicable regulatory requirements. The protocol, amendments, informed consent forms, and translations were approved by Schulman central institutional review board (Cincinnati, Ohio, USA) prior to commencement of the study. Written informed consent was obtained from all participants prior to enrollment. The study protocol and the statistical analysis plan are available online at ClinicalTrials.gov where the study was registered (NCT03342898).

Participants

Healthy adults aged 18–60 years were eligible for enrollment in the study. Exclusion criteria included fever (≥38°C) within three days of vaccination; known hypersensitivity or allergy to the vaccine or components; contraindications to YF-17D vaccine receipt; any serious chronic or progressive disease; altered immune function; body mass index ≥ 35kg/m²; pregnancy or breastfeeding; participation in another clinical trial within 30 days; receipt of vaccines prior to enrollment (14 days for inactivated, 28 days for live vaccines); previous vaccination against any flavivirus or tick-borne encephalitis; current or previous flavivirus infection and ≥1 year living in a dengue-endemic area.

Study design

This phase 3, observer-blind, placebo-controlled randomized study was conducted at 11 sites across the US between February 2018 and May 2019. Participants were randomized 1:1:1 at enrollment using sequence of random numbers centrally-generated in blocks of 6 participants. The vaccine scheme for each of the groups is shown in Fig 1. Group 1 received YF-17D plus placebo at Month 0, TAK-003 at Month 3, and TAK-003 at Month 6. Group 2 received TAK-003 plus placebo at Month 0, TAK-003 at Month 3, and YF-17D at Month 6. Group 3 received TAK-003 and YF-17D at Month 0, TAK-003 at Month 3, and placebo at Month 6. This study design allowed for YF-17D and TAK-003 control groups up until the second injection at Month 3. Participants were followed for approximately six months following the third vaccination, leading to a total study duration of 12 months. All study participants, the site personnel responsible for the evaluation of the study endpoint, and relevant sponsor staff were kept blinded to the random assignment until completion of the study and database lock. Due to differences in the appearance of the study vaccines, vaccines were prepared and administered by qualified unblinded personnel who did not participate in any of the study assessments.

Download:

Fig 1. Study design.

TAK-003, tetravalent dengue vaccine candidate; YF-17D, live attenuated yellow fever vaccine.

https://doi.org/10.1371/journal.pntd.0011124.g001

Procedures

Blood samples were collected pre-vaccination at baseline (Month 0) and post-vaccination on Months 1, 3, 4, 6, and 7. Blood samples obtained at Months 3 and 6 were collected prior to the scheduled Month 3 and 6 vaccinations. Assessment of GMTs of YF neutralizing antibodies was performed using a validated plaque reduction neutralization test (Q2 Solutions, California, USA) at baseline and Months 1, 6, and 7, with GMTs corresponding to the dilution which resulted in a 50% plaque reduction (PRNT₅₀). Seroprotection against YF was defined as reciprocal anti-YF neutralizing antibody titers ≥10 [35]. DENV neutralizing antibodies were assessed by microneutralization assay at all time points, with GMTs corresponding to the dilution which resulted in a 50% plaque reduction (MNT₅₀) [14]. Participants were considered DENV seropositive if they had a reciprocal neutralizing antibody titer ≥10 against any of the four DENV serotypes. Participants were provided with diary cards to record solicited local and systemic adverse events (AEs) for 7 and 14 days after each vaccination, respectively. Unsolicited AEs were collected for 28 days following each vaccination, and serious AEs (SAEs) and medically attended AEs (MAAEs) were recorded throughout the study. AEs were assessed by the investigator for severity (mild, moderate, or severe) and relatedness to the study vaccination.

Vaccines

TAK-003 was provided as a lyophilized formulation which was reconstituted with NaCl solution prior to administration. A single 0.5 mL dose of TAK-003 contained approximately 5.1, 4.5, 5.4, and 5.9 log₁₀ plaque-forming units of TDV-1, TDV-2, TDV-3, and TDV-4, respectively. YF-17D (Stamaril) was also lyophilized and reconstituted with NaCl prior to injection. A single dose contained ≥4.74 log₁₀ pfu YF-17D virus. While the licensed YF-17D vaccine in the US is YF-VAX (Sanofi Pasteur Inc, USA), Stamaril (Sanofi Pasteur Europe, France) was used in this study, in agreement with the FDA, as there was a shortage of YF-VAX at the time of the study. Normal saline for injection (0.9% NaCl) was used as placebo. Concomitant vaccines were administered into opposite arms.

Objectives

The primary study objective was non-inferiority (NI) of the YF seroprotection rate one month after concomitant administration of YF-17D with TAK-003 (Group 3) vs YF-17D with placebo (Group 1).

Secondary objectives included assessments of NI of GMTs of neutralizing antibodies against individual DENV serotypes one month after the second dose of TAK-003 (Month 4) concomitantly administered with YF-17D vs TAK-003 with placebo (Group 3 vs Group 2) and NI of GMTs of neutralizing antibodies against YF, one month following concomitant administration of YF-17D with TAK-003 compared to YF-17D with placebo (Month 1; Group 3 vs Group 1).

Additional secondary immunogenicity objectives were seropositivity rates for individual DENV serotypes, one month post-second dose of TAK-003; GMTs of neutralizing antibodies and the seropositivity rates for all four DENV serotypes, one month post-first dose of TAK-003; GMTs of YF neutralizing antibodies and seroprotection rate in Group 2 one month post-YF-17D; GMTs of neutralizing antibodies and seropositivity rates for all four DENV serotypes one month post-second dose of TAK-003 in Group 1. Safety profiles of each vaccine were also assessed.

Statistical analysis

The sample size of 300 participants per group (assuming approximately 15% drop-out) was sufficient to achieve approximately 90% overall power for demonstrating NI for the primary and secondary objectives. Sample size calculations assumed a one-sided significance level of 0.025 and were performed using nQuery Advisor^® 6.01.

DENV and YF GMTs and seroprotection/seropositivity rates are presented as means with corresponding 95% CIs. Titers below 10 were given an arbitrary value 5. For the primary immunogenicity endpoint, NI was concluded if the upper bound of the 95% CI of the difference in YF seroprotection rates (Group 1 minus Group 3) at Month 1 was <5%. The Newcombe score method was used to compute the 95% CI of the rate difference [36]. For the secondary objectives, NI of DENV GMTs when TAK-003 was concomitantly administered with YF-17D versus with placebo was concluded if the upper bound of the 95% CI for the GMT ratio (Group 2/Group 3) was <2. The NI of YF GMTs when YF-17D was concomitantly administered with TAK-003 versus with placebo was concluded if the upper bound of the 95% CI for the GMT ratio (Group 1/Group 3) was <2. For these assessments, ANOVA (analysis of variance) models were used, including the log-transformed value of titer as dependent variable and group as a factor. Assessment of GMTs and seroprotection/seropositivity rates of sequentially administered vaccines was performed with no formal statistical hypotheses tested.

Data are presented for the per-protocol sets (PPS). The YF PPS, i.e. all randomized participants who received planned Day 1 study vaccination(s) and for whom a valid pre-dose (baseline) and at least one post-dose measurement (Day 30) were available for YF immunogenicity assessments, and who had no major protocol violations, excluding those who were seroprotected for YF virus and/or who were seropositive for any DENV serotype at baseline, was used for assessment of the primary endpoint. The PPS, i.e. all randomized participants who received all planned study vaccinations, who provided a valid baseline measurement and at least one post-vaccination measurement for immunogenicity assessments, and had no major protocol violations, excluding those who were seroprotected for YF virus and/or who were seropositive for any DENV serotype at baseline, was used for assessment of all other immunogenicity endpoints. Safety was analyzed descriptively for the safety set, i.e. all participants who were randomized and received at least one dose of any study vaccines. All statistical analysis was performed using SAS version 9.4.

Results

All 900 randomized participants received at least 1 vaccination. Of them, 723 (80.3%) received the 3 vaccinations, and 739 (82.1%) completed the study follow-up (Fig 2). Discontinuation rates were similar in each group, with majority of participants who did not complete the vaccination regimen and/or the study follow-up being lost to follow-up. Baseline characteristics were similar across the three treatment groups; the mean age was 41 years, 57% were female, and 66% were white (Table 1).

Download:

Fig 2. Participant flowchart.

^aThis includes 1 participant who received YF-17D vaccine instead of Placebo at 3^rd vaccination. AE, adverse event; LTF, lost to follow-up; PD, protocol deviation; TAK-003, tetravalent dengue vaccine candidate; WOC, withdrawal of consent; YF-17D, live attenuated yellow fever vaccine.

https://doi.org/10.1371/journal.pntd.0011124.g002

Download:

Table 1. Demographic and baseline characteristics (safety set).

https://doi.org/10.1371/journal.pntd.0011124.t001

Immunogenicity–yellow fever

The primary study objective of NI of YF seroprotection rate at Month 1 for Groups 1 vs 3 was met (upper bound of the 95% CI for the between-group difference was <5%; Table 2). YF GMTs and seroprotection rates after YF-17D vaccination were high in all groups (Table 3). One month after the first vaccination (Month 1), seroprotection rates were 99.5% (95% CI: 97.4–100.0%) and 99.1 (96.9–99.9%) in Groups 1 (YF-17D plus placebo) and 3 (YF-17D plus TAK-003), respectively. Similarly, the seroprotection rate in Group 2 one month after the YF-17D vaccination (Month 7) was 98.4% (95.4–99.7%). In Group 2, seroprotection rates rose to 9.8% by Month 1 and 12.0% by Month 6, despite not having received the YF-17D vaccine yet.

Download:

Table 2. Non-inferiority comparisons (YF PPS and PPS).

https://doi.org/10.1371/journal.pntd.0011124.t002

Download:

Table 3. Geometric mean titers of anti-YF neutralizing antibodies and seroprotection rates (95% confidence interval) on Days 1 (Month 0), 30 (Month 1), 180 (Month 6), and 210 (Month 7) (YF PPS).

https://doi.org/10.1371/journal.pntd.0011124.t003

The secondary endpoint of NI of YF GMTs between Groups 1 and 3 at Month 1 was also met, as the upper bound of the 95% CI for the GMT ratio was <2 (Table 2). GMTs were of similar magnitude at Month 1 in Groups 1 and 3 (4246 versus 4322), although GMTs were lower in Group 3 than Group 1 by Months 6 and 7 (Table 3). YF GMT in Group 2 (sequential TAK-003 then YF-17D administration) was 3078 one month after YF-17D vaccination.

Immunogenicity–dengue

The secondary objective of NI of DENV neutralizing antibodies was concluded against DENV-2, -3, and -4, as the upper bound of the 95% CI for the GMT ratio between Groups 2 and 3 at Month 4 was <2 (Table 2). However, NI was not concluded against DENV-1, where higher GMTs were observed in Group 2 than Group 3. GMTs against all four DENV serotypes increased post-vaccination with TAK-003 in all three groups. Lower GMTs were observed in Group 3 (concomitant administration of YF-17D and TAK-003) than in Group 2 (sequential TAK-003 then YF-17D) against all serotypes, particularly between TAK-003 doses (Fig 3 and S1 Table). GMTs against DENV-3 and DENV-4 following the first and second dose of TAK-003 were of higher magnitude in Group 1 than those observed at either time point in the other two groups. In Group 2, GMTs against DENV-1, -3, and -4 were of higher magnitude post-YF-17D than just after the first or second dose of TAK-003. When sequentially administered, GMTs against DENV-1, -2, -3, and -4 one month after the second dose of TAK-003 were 268, 2248, 302, and 347 in Group 1 (Month 7); and 297, 2616, 131, and 121 in Group 2 (Month 4). GMTs in the concomitant administration group (Group 3) were 183, 1948, 105, and 98 (Month 4) (S1 Table).

Download:

Fig 3. Geometric mean titers (GMTs) of neutralizing antibodies against each DENV serotype in each of the vaccine groups (PPS).

Number of participants included at each time point are given in the table below the graphs. DENV, dengue virus; PPS, per-protocol set.

https://doi.org/10.1371/journal.pntd.0011124.g003

Seropositivity rates were high in all groups post-vaccination (Fig 4 and S2 Table). Tetravalent seropositivity rates by one month after the second dose of TAK-003 were 99.4% (96.8–100.0%) and 97.0% (93.5–98.9%), in the sequential administration Groups 1 and 2, and 97.7% (94.3–99.4%) in the concomitant administration Group 3. In Group 1, seropositivity rates increased to 4.3–15.8% across serotypes one month after receipt of the YF-17D vaccine but prior to receipt of TAK-003 (Month 1).

Download:

Fig 4. Seropositivity rates (95% confidence intervals) against individual and multiple DENV serotypes in each vaccine group (PPS).

Number of participants included at each time point are given in the table below the graphs. DENV, dengue virus.

https://doi.org/10.1371/journal.pntd.0011124.g004

Safety

Solicited local AEs were reported by 45.9%, 56.4%, and 60.3% of participants in Groups 1, 2, and 3, respectively (Table 4). The majority of these AEs were mild to moderate and did not persist beyond the diary period. The most frequently reported local AE across groups was injection-site pain, with rates varying depending on the vaccine received (TAK-003: 24.9%–42.2% of participants across vaccinations; YF-17D: 10.4–24.1%; placebo: 9.7–16.5%) (S3–S5 Tables). Rates of solicited systemic AEs were similar across groups (55.2%, 59.2%, and 60.6% in Groups 1, 2, and 3, respectively), and mostly mild to moderate (Table 4). The most frequent solicited systemic AE was headache. Rates of solicited AEs tended to decrease with subsequent vaccinations (S6–S8 Tables). Unsolicited AEs were reported by 20.3%, 25.3%, and 21.4% of participants in Groups 1, 2, and 3, respectively. The most commonly occurring AEs were injection site conditions and upper respiratory tract infections (Table 5), with rash reported after TAK-003 by four participants, and after YF-17D by one participant; all these events were considered mild to moderate.

Download:

Table 4. Number (%) of participants reporting solicited local adverse events (AEs) within 7 days or systemic AEs within 14 days after any vaccination overall and by severity (safety set).

https://doi.org/10.1371/journal.pntd.0011124.t004

Download:

Table 5. Number (%) of participants reporting unsolicited adverse events (AEs) within 28 days post vaccination, and the number of events reported by MedDRA system organ class and preferred term.

Data are shown for preferred terms in ≥2% of participants in any vaccine group (safety set).

https://doi.org/10.1371/journal.pntd.0011124.t005

MAAEs were reported by 14.3%, 15.3%, and 15.4% of participants in Groups 1, 2, and 3, respectively. Infections and infestations were the most commonly reported. Six participants reported MAAEs that were considered by the investigator as related to the study vaccinations (fatigue in Group 1; injection site pruritus and injection site bruising in Group 2; lymphangitis, arthralgia, back pain and night sweats in Group 3).

Across groups, twelve participants experienced AEs leading to withdrawal, including two deaths (cardiac arrest and diabetic ketoacidosis, and drug abuse), which were considered unrelated to the study vaccinations. SAEs were reported by 4.3%, 3.3%, and 2.3% of participants in Groups 1, 2, and 3, respectively (S9 Table). None of the SAEs were considered related to the study vaccinations.

Discussion

In this study, NI of the immune response to YF-17D and TAK-003 was demonstrated for concurrent administration of the two vaccines compared to sequential vaccination, except against DENV-1. Some serological cross-reactivity was observed for both vaccines, prior to receipt of the second vaccine.

Marginally lower GMT against DENV-1 was observed one month after the second dose of TAK-003 (Month 4) in the group that received both vaccines (Group 3) compared with the group that received only TAK-003 (Group 2) at this time point. The clinical relevance of this observation is unknown as there is no correlate of protection established for dengue. However, the immune response against DENV-1 was similar to that observed in the clinical development program, specifically the pivotal efficacy trial in subjects who were DENV seronegative prior to vaccination [23]. The seroposivity rates for DENV-1 were also very similar at Month 4 across the 2 groups that had already received 2 doses of TAK-003 at this time point (Groups 2 and 3).

As both vaccines assessed in this study were live attenuated vaccines against flaviviruses, there was the potential for immunological interferences and development of cross-reactive antibodies, leading to altered immunogenicity of one or both of the vaccines. Cross-reactivity of flavivirus antibodies has been observed following sequential natural infections [28, 32, 37, 38], and in our study, YF seroprotection rates increased from zero to 10% after receipt of the first TAK-003 dose, before receipt of YF-17D, suggesting some degree of cross-reactivity. Additionally, co-administration of YF-17D and some other live attenuated vaccines, including other dengue vaccines, has been associated with reduced antibody response [29, 30, 34].

In our study, while NI of the response to the YF-17D vaccine, and to TAK-003 for DENV-2, -3, and -4 was demonstrated, DENV GMTs were numerically lower against all four serotypes 30 days after concomitant administration of the first dose of TAK-003 with YF-17D, compared with administration of TAK-003 alone. However, after the second dose of TAK-003, GMTs were mostly of similar magnitude in Groups 2 and 3, indicating that the effect was transient. The clinical implications of these observed interferences is unknown. Additionally, higher DENV GMTs following sequential vaccination (Groups 1 and 2), when compared with those following concomitant vaccination (Group 3), suggest a potential immune-enhancing effect of YF-17D (when administered prior to or after TAK-003) on TAK-003 antibody responses. Additionally, YF GMTs at Months 6 and 7 were higher in Group 1 than in Group 3 but were lower in Group 2 at Month 7 than in Groups 1 and 3 at Month 1, signaling that these immune interferences are complex, and may be influenced by the time and sequence of vaccination. As YF seroprotection rates remained near 100% at all time points post-sequential vaccination, this likely has no clinical impact for YF-17D vaccination. For TAK-003 vaccination, the clinical significance of this potential enhancing effect following sequential vaccination is currently unknown in absence of any immune correlates of protection for dengue.

The short duration of follow up for immunogenicity endpoints (one month following receipt of the last vaccination) was a limitation for this particular study. While antibody persistence and long-term safety has been reported from a four-year study in children and adolescents living in endemic areas of Latin America and Asia [21], the immunogenicity findings may be different in individuals living in non-endemic areas, who do not experience exposure to natural infection. Therefore, to assess long-term antibody persistence and safety in non-endemic areas, including the effect of a booster dose, an ongoing extension study is being performed in adolescents and adults who participated in two other phase 3 studies in the US and Mexico (NCT03999996). An additional limitation was the relatively high number of participants who prematurely discontinued the vaccination regimen and/or the trial follow-up, mainly as participants were lost to follow-up (Fig 2). The loss was balanced across the three treatment groups, which reduced the impact on the study findings, however the overall population size was slightly below that predicted for the power calculations.

One of the strengths of this study was that the design allowed analysis of concomitant and sequential administration of TAK-003 and YF-17D in a large group of participants who were seronegative for both diseases. As there is already a wealth of data available for both vaccines administered separately, we also chose not to include single vaccine groups to maximize the number of participants receiving the two vaccines concomitantly or sequentially. Performing the study in a non-endemic area for either virus allowed us to assess vaccine interactions without any additional impact of flavivirus exposure, either previously or during the study, as well as adding to the safety database of TAK-003 in seronegative vaccine recipients. Both vaccines in the study were well tolerated, and the safety profile of TAK-003 was similar to that observed in previous studies across baseline seronegative and seropositive participants [16–23]. Most solicited AEs were transient and mild to moderate in severity, with the most frequently reported AEs being injection site pain and headache, as observed previously in phase 2 studies [19–22]. Unsolicited AEs were mainly self-limiting and also similar to those observed in previous studies, and for other live-attenuated dengue vaccines [19–22,29].

In summary, no reduction in immune response to YF-17D vaccine, nor in immune responses to TAK-003 for DENV-2, -3, and -4, was observed when the 2 vaccines are co-administered. Marginally lower DENV-1 GMTs were observed. The clinical relevance of this is unknown but these titers remain similar to those observed in other trials, in particular in the pivotal efficacy trial that demonstrated the efficacy of TAK-003 against dengue cases (including those caused by DENV-1) in subjects who were DENV seronegative prior vaccination.

Supporting information

S1 CONSORT checklist.

https://doi.org/10.1371/journal.pntd.0011124.s001

(DOC)

S1 Table. Geometric mean titers (95% confidence interval) of neutralizing antibodies measured by microneutralization assay (MNT₅₀) for each DENV serotype.

https://doi.org/10.1371/journal.pntd.0011124.s002

(PDF)

S2 Table. Seropositivity rates (95% confidence interval) against each DENV serotype.

https://doi.org/10.1371/journal.pntd.0011124.s003

(PDF)

S3 Table. Number (%) of participants reporting solicited local adverse events (AEs) within 7 days after the first vaccination by severity (safety set).

https://doi.org/10.1371/journal.pntd.0011124.s004

(PDF)

S4 Table. Number (%) of participants reporting solicited local adverse events (AEs) within 7 days after the second vaccination by severity (safety set).

https://doi.org/10.1371/journal.pntd.0011124.s005

(PDF)

S5 Table. Number (%) of participants reporting solicited local adverse events (AEs) within 7 days after the third vaccination by severity (safety set).

https://doi.org/10.1371/journal.pntd.0011124.s006

(PDF)

S6 Table. Number (%) of participants reporting solicited systemic adverse events (AEs) within 14 days after the first vaccination by severity (safety set).

https://doi.org/10.1371/journal.pntd.0011124.s007

(PDF)

S7 Table. Number (%) of participants reporting solicited systemic adverse events (AEs) within 14 days after the second vaccination by severity (safety set).

https://doi.org/10.1371/journal.pntd.0011124.s008

(PDF)

S8 Table. Number (%) of participants reporting solicited systemic adverse events (AEs) within 14 days after the third vaccination by severity (safety set).

https://doi.org/10.1371/journal.pntd.0011124.s009

(PDF)

S9 Table. Serious adverse events (SAEs) by MedDRA system organ class and preferred term after any vaccination (safety set).

https://doi.org/10.1371/journal.pntd.0011124.s010

(PDF)

Acknowledgments

The authors would like to thank all the participants in the study, the clinical staff at the study sites, and the CRO and Takeda staff who contributed to the study team, and Dr Jennifer Engelmoer (Sula Communications) for editorial assistance in the preparation of this manuscript.

References

1. World Health Organization. Ten threats to global health in 2019 [6 April 2020]. Available from: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019.
- View Article
- Google Scholar
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507. pmid:23563266
- View Article
- PubMed/NCBI
- Google Scholar
3. Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. The current and future global distribution and population at risk of dengue. Nature Microbiology. 2019;4(9):1508–1515. pmid:31182801
- View Article
- PubMed/NCBI
- Google Scholar
4. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016;16(8):935–41. pmid:27091092
- View Article
- PubMed/NCBI
- Google Scholar
5. World Health Organization. Yellow fever fact sheet 2019 [cited 29 April 2020]. Available from: https://www.who.int/news-room/fact-sheets/detail/yellow-fever.
- View Article
- Google Scholar
6. Rogers DJ, Wilson AJ, Hay SI, Graham AJ. The global distribution of yellow fever and dengue. Adv Parasitol. 2006;62:181–220. pmid:16647971
- View Article
- PubMed/NCBI
- Google Scholar
7. Tomori O. Yellow fever: the recurring plague. Crit Rev Clin Lab Sci. 2004;41(4):391–427. pmid:15487593
- View Article
- PubMed/NCBI
- Google Scholar
8. Frierson JG. The yellow fever vaccine: a history. Yale J Biol Med. 2010;83(2):77–85. pmid:20589188
- View Article
- PubMed/NCBI
- Google Scholar
9. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89(3):434–444. pmid:24006295
- View Article
- PubMed/NCBI
- Google Scholar
10. Wieten RW, Jonker EF, van Leeuwen EM, Remmerswaal EB, Ten Berge IJ, de Visser AW, et al. A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS One. 2016;11(3):e0149871. pmid:26977808
- View Article
- PubMed/NCBI
- Google Scholar
11. World Health Organization. International Health Regulations, Third Edition 2005 [cited 25 May 2020]. Available from: https://www.who.int/ihr/publications/9789241580496/en/.
12. Huang CY, Kinney RM, Livengood JA, Bolling B, Arguello JJ, Luy BE, et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013;7(5):e2243. pmid:23738026
- View Article
- PubMed/NCBI
- Google Scholar
13. Yoksan S BN, Halstead SB., editor Dengue virus vaccine development: study on biological markers of uncloned dengue 1–4 viruses serially passaged in primary kidney cells. Arbovirus research in Australia: Proceedings of the 4th Symposium Brisbane, Australia: Commonwealth Scientific and Industrial Research Organization, Division of Tropical Animal Science and Queensland Institute of Medical Research; 1986.
- View Article
- Google Scholar
14. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. 2011;29(42):7251–7260. pmid:21777638
- View Article
- PubMed/NCBI
- Google Scholar
15. Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines. 2016;15(4):497–508. pmid:26635182
- View Article
- PubMed/NCBI
- Google Scholar
16. George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, et al. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial. J Infect Dis. 2015;212(7):1032–1041. pmid:25791116
- View Article
- PubMed/NCBI
- Google Scholar
17. Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis. 2014;14(9):830–838. pmid:25087476
- View Article
- PubMed/NCBI
- Google Scholar
18. Rupp R, Luckasen GJ, Kirstein JL, Osorio JE, Santangelo JD, Raanan M, et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. Vaccine. 2015;33(46):6351–6359. pmid:26384447
- View Article
- PubMed/NCBI
- Google Scholar
19. Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, et al. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J Infect Dis. 2016;213(10):1562–1572. pmid:26704612
- View Article
- PubMed/NCBI
- Google Scholar
20. Tricou V, Low JG, Oh HM, Leo Y-S, Kalimuddin S, Wijaya L, et al. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial. Vaccine. 2020;38(6):1513–1519. pmid:31843269
- View Article
- PubMed/NCBI
- Google Scholar
21. Tricou V, Sáez-Llorens X, Yu D, Rivera L, Jimeno J, Villarreal AC, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial. Lancet. 2020;395(10234):1434–1443. pmid:32197107
- View Article
- PubMed/NCBI
- Google Scholar
22. Turner M, Papadimitriou A, Winkle P, Segall N, Levin M, Doust M, et al. Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial. Hum Vaccin Immunother. 2020:1–9. pmid:32119591
- View Article
- PubMed/NCBI
- Google Scholar
23. Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med. 2019;381(21):2009–2019. pmid:31693803
- View Article
- PubMed/NCBI
- Google Scholar
24. Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020;395(10234):1423–1433. pmid:32197105
- View Article
- PubMed/NCBI
- Google Scholar
25. López-Medina E, Biswal S, Saez-Llorens X, et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination. J Infect Dis 2020;jiaa761. pmid:33319249
- View Article
- PubMed/NCBI
- Google Scholar
26. Rivera L, Biswal S, Saez-Llorens X, et al. Three years efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis 2021;ciab864. pmid:34606595
- View Article
- PubMed/NCBI
- Google Scholar
27. Centers for Disease Control and Prevention. Vaccine Recommendations and Guidelines of the ACIP. Timing and Spacing of Immunobiologics 2020 [cited 11 May 2020]. Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
- View Article
- Google Scholar
28. Makino Y, Tadano M, Saito M, Maneekarn N, Sittisombut N, Sirisanthana V, et al. Studies on serological cross-reaction in sequential flavivirus infections. Microbiol Immunol. 1994;38(12):951–955. pmid:7723688
- View Article
- PubMed/NCBI
- Google Scholar
29. Kirstein J, Douglas W, Thakur M, Boaz M, Papa T, Skipetrova A, et al. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults. BMC Infect Dis. 2018;18(1):475. pmid:30241510
- View Article
- PubMed/NCBI
- Google Scholar
30. López P, Lanata CF, Zambrano B, Cortés M, Andrade T, Amemiya I, et al. Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru: A Randomized Trial. Pediatr Infect Dis J. 2016;35(10):1140–1147. pmid:27254034
- View Article
- PubMed/NCBI
- Google Scholar
31. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006;2(2):60–67. pmid:17012873
- View Article
- PubMed/NCBI
- Google Scholar
32. Kanesa-Thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, et al. Atypical antibody responses in dengue vaccine recipients. Am J Trop Med Hyg. 2003;69(6 Suppl):32–38. pmid:14740953
- View Article
- PubMed/NCBI
- Google Scholar
33. Bradt V, Malafa S, von Braun A, Jarmer J, Tsouchnikas G, Medits I, et al. Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination. npj Vaccines. 2019;4(1):38. pmid:31508246
- View Article
- PubMed/NCBI
- Google Scholar
34. Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29(37):6327–6334. pmid:21640779
- View Article
- PubMed/NCBI
- Google Scholar
35. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–1065. pmid:20463105
- View Article
- PubMed/NCBI
- Google Scholar
36. Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17(22):2635–2650. pmid:9839354
- View Article
- PubMed/NCBI
- Google Scholar
37. Mansfield KL, Horton DL, Johnson N, Li L, Barrett ADT, Smith DJ, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92(Pt 12):2821–2829. pmid:21900425
- View Article
- PubMed/NCBI
- Google Scholar
38. Oliveira RA, de Oliveira-Filho EF, Fernandes AI, Brito CA, Marques ET, Tenório MC, et al. Previous dengue or Zika virus exposure can drive to infection enhancement or neutralisation of other flaviviruses. Mem Inst Oswaldo Cruz. 2019;114:e190098. pmid:31411310
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. World Health Organization. Ten threats to global health in 2019 [6 April 2020]. Available from: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019.
View Article
Google Scholar

[2] View Article

[3] Google Scholar

[ref2] 2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507. pmid:23563266
View Article
PubMed/NCBI
Google Scholar

[5] View Article

[6] PubMed/NCBI

[7] Google Scholar

[ref3] 3. Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. The current and future global distribution and population at risk of dengue. Nature Microbiology. 2019;4(9):1508–1515. pmid:31182801
View Article
PubMed/NCBI
Google Scholar

[9] View Article

[10] PubMed/NCBI

[11] Google Scholar

[ref4] 4. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016;16(8):935–41. pmid:27091092
View Article
PubMed/NCBI
Google Scholar

[13] View Article

[14] PubMed/NCBI

[15] Google Scholar

[ref5] 5. World Health Organization. Yellow fever fact sheet 2019 [cited 29 April 2020]. Available from: https://www.who.int/news-room/fact-sheets/detail/yellow-fever.
View Article
Google Scholar

[17] View Article

[18] Google Scholar

[ref6] 6. Rogers DJ, Wilson AJ, Hay SI, Graham AJ. The global distribution of yellow fever and dengue. Adv Parasitol. 2006;62:181–220. pmid:16647971
View Article
PubMed/NCBI
Google Scholar

[20] View Article

[21] PubMed/NCBI

[22] Google Scholar

[ref7] 7. Tomori O. Yellow fever: the recurring plague. Crit Rev Clin Lab Sci. 2004;41(4):391–427. pmid:15487593
View Article
PubMed/NCBI
Google Scholar

[24] View Article

[25] PubMed/NCBI

[26] Google Scholar

[ref8] 8. Frierson JG. The yellow fever vaccine: a history. Yale J Biol Med. 2010;83(2):77–85. pmid:20589188
View Article
PubMed/NCBI
Google Scholar

[28] View Article

[29] PubMed/NCBI

[30] Google Scholar

[ref9] 9. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89(3):434–444. pmid:24006295
View Article
PubMed/NCBI
Google Scholar

[32] View Article

[33] PubMed/NCBI

[34] Google Scholar

[ref10] 10. Wieten RW, Jonker EF, van Leeuwen EM, Remmerswaal EB, Ten Berge IJ, de Visser AW, et al. A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS One. 2016;11(3):e0149871. pmid:26977808
View Article
PubMed/NCBI
Google Scholar

[36] View Article

[37] PubMed/NCBI

[38] Google Scholar

[ref11] 11. World Health Organization. International Health Regulations, Third Edition 2005 [cited 25 May 2020]. Available from: https://www.who.int/ihr/publications/9789241580496/en/.

[ref12] 12. Huang CY, Kinney RM, Livengood JA, Bolling B, Arguello JJ, Luy BE, et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013;7(5):e2243. pmid:23738026
View Article
PubMed/NCBI
Google Scholar

[41] View Article

[42] PubMed/NCBI

[43] Google Scholar

[ref13] 13. Yoksan S BN, Halstead SB., editor Dengue virus vaccine development: study on biological markers of uncloned dengue 1–4 viruses serially passaged in primary kidney cells. Arbovirus research in Australia: Proceedings of the 4th Symposium Brisbane, Australia: Commonwealth Scientific and Industrial Research Organization, Division of Tropical Animal Science and Queensland Institute of Medical Research; 1986.
View Article
Google Scholar

[45] View Article

[46] Google Scholar

[ref14] 14. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. 2011;29(42):7251–7260. pmid:21777638
View Article
PubMed/NCBI
Google Scholar

[48] View Article

[49] PubMed/NCBI

[50] Google Scholar

[ref15] 15. Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines. 2016;15(4):497–508. pmid:26635182
View Article
PubMed/NCBI
Google Scholar

[52] View Article

[53] PubMed/NCBI

[54] Google Scholar

[ref16] 16. George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, et al. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial. J Infect Dis. 2015;212(7):1032–1041. pmid:25791116
View Article
PubMed/NCBI
Google Scholar

[56] View Article

[57] PubMed/NCBI

[58] Google Scholar

[ref17] 17. Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis. 2014;14(9):830–838. pmid:25087476
View Article
PubMed/NCBI
Google Scholar

[60] View Article

[61] PubMed/NCBI

[62] Google Scholar

[ref18] 18. Rupp R, Luckasen GJ, Kirstein JL, Osorio JE, Santangelo JD, Raanan M, et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. Vaccine. 2015;33(46):6351–6359. pmid:26384447
View Article
PubMed/NCBI
Google Scholar

[64] View Article

[65] PubMed/NCBI

[66] Google Scholar

[ref19] 19. Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, et al. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J Infect Dis. 2016;213(10):1562–1572. pmid:26704612
View Article
PubMed/NCBI
Google Scholar

[68] View Article

[69] PubMed/NCBI

[70] Google Scholar

[ref20] 20. Tricou V, Low JG, Oh HM, Leo Y-S, Kalimuddin S, Wijaya L, et al. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial. Vaccine. 2020;38(6):1513–1519. pmid:31843269
View Article
PubMed/NCBI
Google Scholar

[72] View Article

[73] PubMed/NCBI

[74] Google Scholar

[ref21] 21. Tricou V, Sáez-Llorens X, Yu D, Rivera L, Jimeno J, Villarreal AC, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial. Lancet. 2020;395(10234):1434–1443. pmid:32197107
View Article
PubMed/NCBI
Google Scholar

[76] View Article

[77] PubMed/NCBI

[78] Google Scholar

[ref22] 22. Turner M, Papadimitriou A, Winkle P, Segall N, Levin M, Doust M, et al. Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial. Hum Vaccin Immunother. 2020:1–9. pmid:32119591
View Article
PubMed/NCBI
Google Scholar

[80] View Article

[81] PubMed/NCBI

[82] Google Scholar

[ref23] 23. Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med. 2019;381(21):2009–2019. pmid:31693803
View Article
PubMed/NCBI
Google Scholar

[84] View Article

[85] PubMed/NCBI

[86] Google Scholar

[ref24] 24. Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020;395(10234):1423–1433. pmid:32197105
View Article
PubMed/NCBI
Google Scholar

[88] View Article

[89] PubMed/NCBI

[90] Google Scholar

[ref25] 25. López-Medina E, Biswal S, Saez-Llorens X, et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination. J Infect Dis 2020;jiaa761. pmid:33319249
View Article
PubMed/NCBI
Google Scholar

[92] View Article

[93] PubMed/NCBI

[94] Google Scholar

[ref26] 26. Rivera L, Biswal S, Saez-Llorens X, et al. Three years efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis 2021;ciab864. pmid:34606595
View Article
PubMed/NCBI
Google Scholar

[96] View Article

[97] PubMed/NCBI

[98] Google Scholar

[ref27] 27. Centers for Disease Control and Prevention. Vaccine Recommendations and Guidelines of the ACIP. Timing and Spacing of Immunobiologics 2020 [cited 11 May 2020]. Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
View Article
Google Scholar

[100] View Article

[101] Google Scholar

[ref28] 28. Makino Y, Tadano M, Saito M, Maneekarn N, Sittisombut N, Sirisanthana V, et al. Studies on serological cross-reaction in sequential flavivirus infections. Microbiol Immunol. 1994;38(12):951–955. pmid:7723688
View Article
PubMed/NCBI
Google Scholar

[103] View Article

[104] PubMed/NCBI

[105] Google Scholar

[ref29] 29. Kirstein J, Douglas W, Thakur M, Boaz M, Papa T, Skipetrova A, et al. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults. BMC Infect Dis. 2018;18(1):475. pmid:30241510
View Article
PubMed/NCBI
Google Scholar

[107] View Article

[108] PubMed/NCBI

[109] Google Scholar

[ref30] 30. López P, Lanata CF, Zambrano B, Cortés M, Andrade T, Amemiya I, et al. Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru: A Randomized Trial. Pediatr Infect Dis J. 2016;35(10):1140–1147. pmid:27254034
View Article
PubMed/NCBI
Google Scholar

[111] View Article

[112] PubMed/NCBI

[113] Google Scholar

[ref31] 31. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006;2(2):60–67. pmid:17012873
View Article
PubMed/NCBI
Google Scholar

[115] View Article

[116] PubMed/NCBI

[117] Google Scholar

[ref32] 32. Kanesa-Thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, et al. Atypical antibody responses in dengue vaccine recipients. Am J Trop Med Hyg. 2003;69(6 Suppl):32–38. pmid:14740953
View Article
PubMed/NCBI
Google Scholar

[119] View Article

[120] PubMed/NCBI

[121] Google Scholar

[ref33] 33. Bradt V, Malafa S, von Braun A, Jarmer J, Tsouchnikas G, Medits I, et al. Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination. npj Vaccines. 2019;4(1):38. pmid:31508246
View Article
PubMed/NCBI
Google Scholar

[123] View Article

[124] PubMed/NCBI

[125] Google Scholar

[ref34] 34. Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29(37):6327–6334. pmid:21640779
View Article
PubMed/NCBI
Google Scholar

[127] View Article

[128] PubMed/NCBI

[129] Google Scholar

[ref35] 35. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–1065. pmid:20463105
View Article
PubMed/NCBI
Google Scholar

[131] View Article

[132] PubMed/NCBI

[133] Google Scholar

[ref36] 36. Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17(22):2635–2650. pmid:9839354
View Article
PubMed/NCBI
Google Scholar

[135] View Article

[136] PubMed/NCBI

[137] Google Scholar

[ref37] 37. Mansfield KL, Horton DL, Johnson N, Li L, Barrett ADT, Smith DJ, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92(Pt 12):2821–2829. pmid:21900425
View Article
PubMed/NCBI
Google Scholar

[139] View Article

[140] PubMed/NCBI

[141] Google Scholar

[ref38] 38. Oliveira RA, de Oliveira-Filho EF, Fernandes AI, Brito CA, Marques ET, Tenório MC, et al. Previous dengue or Zika virus exposure can drive to infection enhancement or neutralisation of other flaviviruses. Mem Inst Oswaldo Cruz. 2019;114:e190098. pmid:31411310
View Article
PubMed/NCBI
Google Scholar

[143] View Article

[144] PubMed/NCBI

[145] Google Scholar

Figures

Abstract

Background

Methods

Results

Conclusions

Trial registration

Author summary

Introduction

Methods

Ethics statement

Participants

Study design

Procedures

Vaccines

Objectives

Statistical analysis

Results

Immunogenicity–yellow fever

Immunogenicity–dengue

Safety

Discussion

Supporting information

S1 CONSORT checklist.

S1 Table. Geometric mean titers (95% confidence interval) of neutralizing antibodies measured by microneutralization assay (MNT50) for each DENV serotype.

S2 Table. Seropositivity rates (95% confidence interval) against each DENV serotype.

S3 Table. Number (%) of participants reporting solicited local adverse events (AEs) within 7 days after the first vaccination by severity (safety set).

S4 Table. Number (%) of participants reporting solicited local adverse events (AEs) within 7 days after the second vaccination by severity (safety set).

S5 Table. Number (%) of participants reporting solicited local adverse events (AEs) within 7 days after the third vaccination by severity (safety set).

S6 Table. Number (%) of participants reporting solicited systemic adverse events (AEs) within 14 days after the first vaccination by severity (safety set).

S7 Table. Number (%) of participants reporting solicited systemic adverse events (AEs) within 14 days after the second vaccination by severity (safety set).

S8 Table. Number (%) of participants reporting solicited systemic adverse events (AEs) within 14 days after the third vaccination by severity (safety set).

S9 Table. Serious adverse events (SAEs) by MedDRA system organ class and preferred term after any vaccination (safety set).

Acknowledgments

References

S1 Table. Geometric mean titers (95% confidence interval) of neutralizing antibodies measured by microneutralization assay (MNT₅₀) for each DENV serotype.